Mainz Biomed B.V.
MYNZNASDAQHealthcare
$3.59
+$0.03(+0.84%)
Market Cap$14691084
P/E Ratio—
52W High$5.34
52W Low$0.5476
Mainz Biomed B.V. (MYNZ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MYNZ · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Sep 26, 2025EPS Actual
-$2.65
Revenue
$0.00B
Est. $0.00B · -42.3%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Sep 26, 2025
After Market Close
▼ Miss Revenue
MYNZ reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Apr 14, 2026 | -$1.01 | — | — | — | $0.00B | — |
| — Q3 FY2025 | Sep 26, 2025 | — | -$2.65 | — | $0.00B | $0.00B | -42.3% |
| ▼ Q2 FY2025 | Apr 8, 2025 | -$3.60 | -$9.60 | -166.7% | $0.00B | — | — |
| ▼ Q4 FY2024 | Dec 26, 2024 | -$4.40 | -$15.60 | -254.6% | $0.00B | $0.00B | -13.2% |
| ▼ Q2 FY2024 | Apr 9, 2024 | -$0.32 | -$9.60 | -2900.0% | $0.00B | $0.00B | -2.4% |
| ▲ Q4 FY2023 | Nov 16, 2023 | -$20.00 | -$15.60 | +22.0% | $0.00B | $0.00B | +100.1% |
| ▲ Q2 FY2023 | May 16, 2023 | -$18.80 | -$18.00 | +4.3% | $0.00B | $0.00B | -5.7% |
| ▼ Q4 FY2022 | Nov 2, 2022 | -$0.43 | -$0.97 | -125.9% | $0.00B | — | — |
Q2 FY2026
Apr 14, 2026
EPS Actual
—
EPS Est.
-$1.01
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 26, 2025
EPS Actual
-$2.65
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 8, 2025Miss
EPS Actual
-$9.60
EPS Est.
-$3.60
EPS Surpr.
-166.7%
Revenue
$0.00B
Q4 FY2024
Dec 26, 2024Miss
EPS Actual
-$15.60
EPS Est.
-$4.40
EPS Surpr.
-254.6%
Revenue
$0.00B
Q2 FY2024
Apr 9, 2024Miss
EPS Actual
-$9.60
EPS Est.
-$0.32
EPS Surpr.
-2900.0%
Revenue
$0.00B
Q4 FY2023
Nov 16, 2023Beat
EPS Actual
-$15.60
EPS Est.
-$20.00
EPS Surpr.
+22.0%
Revenue
$0.00B
Q2 FY2023
May 16, 2023Beat
EPS Actual
-$18.00
EPS Est.
-$18.80
EPS Surpr.
+4.3%
Revenue
$0.00B
Q4 FY2022
Nov 2, 2022Miss
EPS Actual
-$0.97
EPS Est.
-$0.43
EPS Surpr.
-125.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q3 FY2028 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Q2 FY2028 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q1 FY2028 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $-1.01 | $-1.01 | $-1.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Sep 26, 2025 | — | $1.55 | $1.55 | +0.00% |
| ▼ Q2 FY2025 | Apr 8, 2025 | -166.7% | $3.18 | $3.06 | -3.77% |
| ▼ Q4 FY2024 | Dec 26, 2024 | -254.6% | $4.82 | $4.54 | -5.81% |
| ▼ Q2 FY2024 | Apr 9, 2024 | -2900.0% | $43.20 | $39.60 | -8.33% |
| ▲ Q4 FY2023 | Nov 16, 2023 | +22.0% | $48.40 | $46.00 | -4.96% |
| ▲ Q2 FY2023 | May 16, 2023 | +4.3% | $219.60 | $214.80 | -2.19% |
| ▼ Q4 FY2022 | Nov 2, 2022 | -125.9% | $286.00 | $283.60 | -0.84% |
| — Q2 FY2022 | May 2, 2022 | — | $497.60 | $516.00 | +3.70% |
Q3 FY2025+0.00%
Report Date
Sep 26, 2025
EPS Beat/Miss
—
Price Before
$1.55
Price After
$1.55
Q2 FY2025-3.77%
Report Date
Apr 8, 2025
EPS Beat/Miss
-166.7%
Price Before
$3.18
Price After
$3.06
Q4 FY2024-5.81%
Report Date
Dec 26, 2024
EPS Beat/Miss
-254.6%
Price Before
$4.82
Price After
$4.54
Q2 FY2024-8.33%
Report Date
Apr 9, 2024
EPS Beat/Miss
-2900.0%
Price Before
$43.20
Price After
$39.60
Q4 FY2023-4.96%
Report Date
Nov 16, 2023
EPS Beat/Miss
+22.0%
Price Before
$48.40
Price After
$46.00
Q2 FY2023-2.19%
Report Date
May 16, 2023
EPS Beat/Miss
+4.3%
Price Before
$219.60
Price After
$214.80
Q4 FY2022-0.84%
Report Date
Nov 2, 2022
EPS Beat/Miss
-125.9%
Price Before
$286.00
Price After
$283.60
Q2 FY2022+3.70%
Report Date
May 2, 2022
EPS Beat/Miss
—
Price Before
$497.60
Price After
$516.00
Avg Beat Reaction-3.58%
Avg Miss Reaction-4.69%
Beat Rate2 / 8 quarters
Largest Move-8.33% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MYNZ ends December
Mainz Biomed B.V. (MYNZ) most recently reported earnings on September 26, 2025 for Q3 FY2025, posting EPS of $-2.65 (in line with the analyst consensus of —). The next MYNZ earnings date is expected around September 1, 2026.
Each quarter, investors track MYNZ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MYNZ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MYNZ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MYNZ earnings · 4 questionsMainz Biomed B.V.'s next earnings report is expected around September 1, 2026. MYNZ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MYNZ historically reports after market close (AMC).
MYNZ earnings datewhen is MYNZ earningsMYNZ next earnings datewhen does MYNZ report earningsMYNZ earnings calendar
▸ Source: FMP · Mainz Biomed B.V. SEC filings · US GAAP · Mainz Biomed B.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026